{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:44:33Z","timestamp":1786221873216,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-034599"],"award-info":[{"award-number":["INV-034599"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.vaccine.2023.06.059","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T13:39:58Z","timestamp":1687613998000},"page":"4808-4822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India"],"prefix":"10.1016","volume":"41","author":[{"given":"Anita","family":"Chaudhary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3241-5457","authenticated-orcid":false,"given":"Ramya","family":"Madhavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Babji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7247-537X","authenticated-orcid":false,"given":"Reshma","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanduni","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajith","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poornima","family":"Saravanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Origanti","family":"Sharon Nikitha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian Vivek","family":"Leander Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenita Sharon","family":"David Chelladurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpitha Anbu","family":"Deborah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9401-0944","authenticated-orcid":false,"given":"Anna","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3656-564X","authenticated-orcid":false,"given":"Gagandeep","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3496-2588","authenticated-orcid":false,"given":"Winsley","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.06.059_b0005","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.2021.19499","article-title":"Association between mRNA vaccination and COVID-19 hospitalization and disease severity","volume":"326","author":"Tenforde","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.06.059_b0010","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1016\/S2214-109X(22)00112-7","article-title":"Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study","volume":"10","author":"Jara","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2023.06.059_b0015","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study","volume":"373","author":"Lopez Bernal","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2023.06.059_b0020","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.06.059_b0025","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.06.059_b0030","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.06.059_b0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32265-5","article-title":"SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort","volume":"13","author":"Aldridge","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.06.059_b0040","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","article-title":"SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion","volume":"599","author":"Mlcochova","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.06.059_b0045","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/S0140-6736(21)02758-6","article-title":"Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic","volume":"398","author":"Karim","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.06.059_b0050","article-title":"COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron","volume":"10","author":"Suntronwong","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.06.059_b0055","unstructured":"Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons [Internet]. [cited 2023 Mar 15]; Available from: https:\/\/www.who.int\/publications-detail-redirect\/WHO-2019-nCoV-vaccines-SAGE_recommendation-immunocompromised-persons."},{"key":"10.1016\/j.vaccine.2023.06.059_b0060","unstructured":"Interim statement on the use of additional booster doses of Emergency Use Listed mRNA vaccines against COVID-19 [Internet]. [cited 2023 Mar 15]; Available from: https:\/\/www.who.int\/news\/item\/17-05-2022-interim-statement-on-the-use-of-additional-booster-doses-of-emergency-use-listed-mrna-vaccines-against-covid-19."},{"key":"10.1016\/j.vaccine.2023.06.059_b0065","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.06.059_b0070","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.06.059_b0075","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study","volume":"399","author":"Costa Clemens","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.06.059_b0080","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/vaccines10010086","article-title":"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine","volume":"10","author":"Kanokudom","year":"2022","journal-title":"Vaccines"},{"issue":"122","key":"10.1016\/j.vaccine.2023.06.059_b0085","first-page":"693","article-title":"Effectiveness of BBV152, Covaxin and AZD1222, Covishield vaccines against severe COVID-19 and B.1.617.2, Delta variant in India, a multi-centric hospital-based case-control study","volume":"2022","author":"Bhatnagar","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.06.059_b0090","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1473-3099(21)00680-0","article-title":"Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses","volume":"22","author":"Thiruvengadam","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.06.059_b0095","article-title":"SARS-CoV-2 reinfection rate and estimated effectiveness of the inactivated whole virion vaccine BBV152 against reinfection among health care workers in New Delhi","volume":"5","author":"Malhotra","year":"2022","journal-title":"India JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2023.06.059_b0100","unstructured":"GuidelinesforCOVID19VaccinationofChildrenbetween15to18yearsandPrecautionDosetoHCWsFLWs&60populationwithcomorbidities.pdf [Internet]. [cited 2023 Feb 25]. - Google Search [Internet]. [cited 2023 Mar 16];Available from: https:\/\/www.google.com\/search?q=GuidelinesforCOVID19VaccinationofChildrenbetween15to18yearsandPrecautionDosetoHCWsFLWs\u00a0%2660populationwithcomorbidities.pdf+\u00a0%5BInternet\u00a0%5D.+\u00a0%5Bcited+2023+Feb+25\u00a0%5D.&rlz=1C5CHFA_enIN905IN908&oq=GuidelinesforCOVID19VaccinationofChildrenbetween15to18yearsandPrecautionDosetoHCWsFLWs\u00a0%2660populationwithcomorbidities.pdf+\u00a0%5BInternet\u00a0%5D.+\u00a0%5Bcited+2023+Feb+25\u00a0%5D.&aqs=chrome..69i57j69i59.346j0j7&sourceid=chrome&ie=UTF-8."},{"key":"10.1016\/j.vaccine.2023.06.059_b0105","doi-asserted-by":"crossref","unstructured":"Rose W, Raju R, Babji S, George A, Madhavan R, Leander Xavier JV, et al. Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD\u2122) and BBV152 (COVAXIN\u00ae): a non-inferiority phase 4, participant and observer-blinded, randomised study. Lancet Reg Health Southeast Asia 2023;100141.","DOI":"10.1016\/j.lansea.2023.100141"},{"key":"10.1016\/j.vaccine.2023.06.059_b0110","unstructured":"GeurtsvanKessel CH, Geers D, Schmitz KS, Mykytyn AZ, Lamers MM, Bogers S, et al. Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients. Sci Immunol:eabo2202."},{"key":"10.1016\/j.vaccine.2023.06.059_b0115","first-page":"249","article-title":"Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants","volume":"3","author":"Miyamoto","year":"2022","journal-title":"Med (N Y)"},{"key":"10.1016\/j.vaccine.2023.06.059_b0120","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1016\/j.vaccine.2021.09.055","article-title":"Antibody response after first and second-dose of ChAdOx1-nCOV (CovishieldTM\u00ae) and BBV-152 (CovaxinTM\u00ae) among health care workers in India: the final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study","volume":"39","author":"Singh","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.059_b0125","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2029111","article-title":"Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study","volume":"18","author":"Wanlapakorn","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.06.059_b0130","doi-asserted-by":"crossref","DOI":"10.1126\/science.abn8934","article-title":"Low protease activity in B cell follicles promotes retention of intact antigens after immunization","volume":"379","author":"Aung","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.06.059_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109664","article-title":"Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2","volume":"36","author":"Dangi","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2023.06.059_b0140","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.it.2014.07.003","article-title":"Influence of the microbiota on vaccine effectiveness","volume":"35","author":"Valdez","year":"2014","journal-title":"Trends Immunol"},{"key":"10.1016\/j.vaccine.2023.06.059_b0145","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.immuni.2021.04.009","article-title":"CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity","volume":"54","author":"Nguyen","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2023.06.059_b0150","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.immuni.2021.04.006","article-title":"CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses","volume":"54","author":"Lineburg","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2023.06.059_b0155","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.add3899","article-title":"Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination","volume":"7","author":"Maringer","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2023.06.059_b0160","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12916-022-02342-z","article-title":"AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2","volume":"20","author":"Chibwana","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2023.06.059_b0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32298-w","article-title":"Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination","volume":"13","author":"Bellusci","year":"2022","journal-title":"Nat Commun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23007442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23007442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:21:11Z","timestamp":1786220471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23007442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":33,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0264410X23007442"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.059","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}